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pituitary adenylate cyclase activating polypeptide (pacap) is a multifunctional neuropeptide occurring 
in the nervous system as well as in the peripheral organs. Beneficial action of PACAP has been shown in 
different pathological processes. The strong protective effects of the peptide are probably due to its com-
plex modulatory actions in antiapoptotic, anti-inflammatory and antioxidant pathways. In the kidney, 
PACAP is protective in models of diabetic nephropathy, myeloma kidney injury, cisplatin-, gentamycin- 
and cyclosporin-induced damages. Numerous studies have been published describing the protective effect 
of this peptide in renal ischemia/reperfusion. the present review focuses on the ischemia/reperfusion-
induced kidney injury and gives a brief summary about the results published in this area.
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introduction
pituitary adenylate cyclase activating polypeptide (pacap) is a neuropeptide of the 
secretin/glucagon/vip peptide family and consists of 38 or 27 amino acids (pacap38 
and PACAP27, respectively). PACAP occurs in all organs and one of the best known 
effects are its cytoprotective actions [50]. The effects of PACAP are mediated by 
G-protein-coupled receptors: the specific PAC1 receptor and VPAC1 and 2 receptors, 
which also bind VIP with similar affinity [23]. In accordance with the widespread 
distribution, PACAP exerts pleiotropic effects [50]. Among others, PACAP has pro-
tective effects in pathological conditions of the nervous system, such as models of 
neurodegenerative diseases, ischemia or traumatic nerve injuries [33, 47]. Similar 
effects have been shown in non-neuronal tissues, such as in the cardiovascular, res-
piratory, gastrointestinal and immune system and in endocrine organs against various 
kinds of harmful stimuli [50]. It is generally accepted that the protective function of 
PACAP is mediated by the antiapoptotic, anti-inflammatory and antioxidant effects: 
PACAP inhibits proapoptotic signaling at several levels, while it stimulates antiapop-
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totic pathways. PACAP also inhibits several proinflammatory cytokines and it also 
elevates the antioxidant capacity [41, 42, 50].
in accordance with the cytoprotective effects in peripheral organs, numerous stud-
ies reported on the nephroprotective effect of this peptide. this nephroprotective 
effect has been shown in animal models of diabetic nephropathy, cisplatin-, cyclo-
sporin-, gentamycin-induced nephrotoxicity, myeloma nephropathy and ischemia/
reperfusion-induced kidney injury [34]. In case of gentamycin-induced kidney injury, 
repeated use of PACAP reduced the increased TNF-α level [3, 27]. In a rat model of 
diabetic nephropathy, iv. PACAP suppressed the increase of the profibrotic cytokine 
TGF-β and that of the proinflammatory cytokine TNF-α. It counteracted the weight 
gain of the kidneys and the enlargement of the glomeruli. In PACAP-treated rats the 
protein level measured in the urine was lower [3, 27]. furthermore, another study 
described that PACAP treatment reduced the severity of the histological alterations in 
diabetic kidneys and decreased the expression of several cytokines [5]. In cyclo-
sporin A-induced kidney damage both in vivo and in vitro studies proved the protec-
tive effect of PACAP [21]. PACAP reduced TGF-β1 expression, the rise of LDH-
levels, decreased apoptosis and the production of oxygen reactive species, suppressed 
the increased expression of the major extracellular matrix components, ameliorated 
the tubulointerstitial damage in the kidney and nearly normalized serum creatinine 
level [21]. In cisplatin-induced kidney injury the administration of PACAP reduced 
the increased level of blood urea nitrogen and serum creatinine, decreased apoptosis 
and the severity of the renal morphological changes. Increase of the level of TNF-α 
both in the plasma and in the kidney could be counteracted by PACAP treatment [28, 
30]. several studies have reported the protective effect of pacap in myeloma 
nephropathy [2, 3, 25–27]. Among others, PACAP was able to reduce TNF-α and 
IL-6 expression as well as the morphological damage of tubular cells. A human case 
report showed that iv. PACAP resulted in reduction of free lambda light chains in the 
urine [26]. It is also known that PACAP increases blood flow of the kidneys and 
stimulates renin secretion through the activation of pac1 receptor [11, 13]. 
Ischemia/reperfusion-induced injuries represent a major problem in the clinical 
practice. Microvascular perfusion failure, no-reflow and tissue hypoxia play a role in 
the pathomechanism of this damage despite reperfusion and reoxygenation. 
Reperfusion following ischemia induces an inflammatory response. Inflammatory 
cells (such as macrophages and neutrophils) taking part in this response produce 
cytokines, chemokines, oxygen free radicals and lipid mediators that contribute to the 
development of the injury. Apoptosis and necrosis are also involved in this process 
[31]. Regarding the kidney, some surgical interventions, kidney transplantation and 
numerous disorders are accompanied by ischemia/reperfusion-induced injury. There 
are several studies dealing with the effect of PACAP in kidney damage caused by 
ischemia/reperfusion, briefly summarized in the present review. 
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Effect of exogenous PACAP in ischemia/reperfusion-induced 
kidney injury
Cytoprotective effects of PACAP in ischemia/reperfusion-induced injuries both in the 
nervous system and the peripheral organs have been reported in several studies. This 
protective effect was first described in global and focal cerebral ischemia [32, 42, 48]. 
Subsequently, the protective effects of PACAP were reported in ischemic injury of the 
retina [4] and in ischemia/reperfusion-induced damages of peripheral organs, such as 
in intestinal, cardiac and liver ischemia/reperfusion [8, 20, 39].
The first study about the role of PACAP in ischemia/reperfusion-induced kidney 
injury was reported by Riera and his coworkers [38]. They showed that administra-
tion of PACAP in continuous infusion (160 pmol/h 7 days long) starting before or 
6 h after warm ischemia attenuated the tubulointerstitial damage in the kidney and 
decreased the serum creatinine level. they also showed that pacap increased the 
plasma cAMP-level, the serum interleukin-6 level and decreased the indicators of 
inflammatory cell infiltration. Based on these results it can be expected that the pro-
tective effect of PACAP in the kidney during ischemia/reperfusion is mediated, at 
least partially, by the anti-inflammatory effect of this peptide. Subsequently, our 
research group described that a single iv. injection of PACAP attenuated the tubular 
damage, ameliorated the survival of the experimental animals and improved the 
ischemic tolerance of the kidney after different times of ischemia/reperfusion [44]. 
Control animals had decreased survival time and their kidneys showed multifocal 
acute tubular atrophy after 45 min ischemia, while 60 min ischemia resulted in pre-
mature death with severe multifocal tubular atrophy in the kidneys in all control rats. 
in contrast, pacap-treated animals survived with mild histological changes follow-
ing 45 min ischemia. pacap-treated rats had higher survival rate after 60 min 
ischemia and kidneys showed only moderate focal tubular alterations. All control rats 
died before the termination of ischemia in case of 75 min ischemia, whereas PACAP-
treated animals survived longer (5–10 days after the ischemia), with the kidneys 
showing severe focal tubular atrophy. 
regarding the protective mechanisms, it is suggested that pacap acts through a 
combination of antiapoptotic, anti-inflammatory and antioxidant actions. Apoptosis 
plays an important role in ischemia/reperfusion-induced kidney injury [40]. The 
antiapoptotic effect of PACAP in the kidney had already been proven in cisplatin- and 
in cyclosporin-induced kidney injury [21, 28]. We found a significant decrease of the 
antiapoptotic Bcl-2 after renal ischemia/reperfusion, reversed by PACAP treatment 
[15]. Cytokines and chemokines also play an important role in the development of 
kidney injury after ischemia/reperfusion [6, 18, 19, 49]. PACAP decreased proinflam-
matory cytokines, like TNF-α and IL-6, in different pathological conditions in the 
kidney [27]. The anti-inflammatory effect of PACAP was also confirmed in renal 
ischemia/reperfusion [15]. Increased expression of some cytokines was reduced by 
preoperative PACAP treatment, such as fractalkine (chemokine ligand 1), sICAM-1 
(soluble intercellular adhesion molecule-1), L-selectin, RANTES (regulated upon 
activation normal t cell expressed and secreted), cntf (ciliary neurotrophic factor), 
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MIP-3α (macrophage inflammatory protein-3α), and TIMP-1 (tissue inhibitor of met-
alloproteinase-1) [15]. Another study has described the decrease of the superoxide 
dismutase (SOD) activity after 60 min ischemia and reperfusion in the kidney [17]. 
This decrease could be counteracted by a single iv. PACAP injection. The results are 
in accordance with the findings of earlier studies, where the changes of SOD activity 
were measured in intestinal ischemia/reperfusion [8]. the protective effect of pacap 
has also been shown in oxidative stress-induced kidney injury in vitro [17]. hydrogen 
peroxide-induced oxidative stress resulted in the decrease of primary rat kidney cell 
survival, that could be dose-dependently attenuated by PACAP treatment.
the protective effect of pacap in a mouse model of ischemia/reperfusion-induced 
kidney injury has also been proven [29]. Intraperitoneal administration of PACAP 
resulted in attenuated tubular alterations and neutrophil accumulation, in addition, 
apoptosis was also decreased. Blood urea nitrogen, serum creatinine, plasma and 
kidney homogenate TNF-α level were lower in PACAP-treated animals. Toll-like 
receptors, which are important mediators of innate immunity in the kidney, were also 
shown to participate in the protective effects of pacap [22, 29]. 
Presence of PACAP and its receptors in the kidney
The presence of PACAP38 both in rat and mouse kidneys has been revealed by mass 
spectrometry and radioimmunoassay [7, 14]. PACAP38- and PACAP27-like immuno-
reactivity could be observed both in the cortex and medulla with the former being 
stronger [1, 7, 45]. We also showed that PACAP38- and PACAP27-like immuno-
reactivity detected in the kidney sensitively reacted to ischemia/reperfusion [45]. 
measurements were performed after 60 min ischemia and 1, 6, 24 h reperfusion. in the 
cortex, an acute decrease of PACAP was followed by a marked increase on the intact 
side, which was not observed on the ischemic side. In the medulla, changes could be 
observed only on the clamped side, where PACAP38-like immunoreactivity showed a 
significant increase. Although the exact mechanism of these changes is not known yet, 
it can be suggested that PACAP increased due to its protective effect. Similar upregu-
lation of PACAP has been found earlier in response to other insults [42, 52]. The 
longer and more expressed increase of pacap in the medulla may explain the higher 
resistance against ischemia. The presence of PACAP receptors has also been shown in 
the urinary system, intensively expressed in kidney cortical tubular epithelial cells [7, 
12, 23, 24, 36, 37, 51]. The localization of the receptors on the tubular epithelial cells 
can explain the attenuated tubular damage in case of PACAP treatment.
The effect of endogenous PACAP in ischemia/reperfusion-induced 
kidney injury
it is suggested that endogenous pacap functions as a protective agent against differ-
ent harmful stimuli [35, 50]. Several studies have found that PACAP deficient mice 
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Fig. 1. Representative photomicrographs of PAS-stained kidney sections from wild-type and PACAP defi-
cient mice. a: cortex of a control (sham-operated) wild-type mouse. Both the malpighian corpuscles and 
the tubuli are intact, the PAS+ glycocalyx layer can be clearly seen. B: Cortex of a wild-type mouse after 45 
min ischemia and reperfusion. Some tubuli filled with cylinders can be observed (thyreoidisation) (arrows). 
The triangle represents a mildly dilated Bowman’s capsule. Moderate tubular dilatation can be also seen 
(asterisk). C: The tubuli are widened in the cortex of a PACAP deficient mouse after 60 min ischemia and 
reperfusion (asterisks). The absence of the PAS-positive glycocalyx is seen on the luminal surface of the 
tubuli. Dilatation of the Bowman’s capsule can be also observed (triangle). D: Cortex of a PACAP deficient 
mouse following 45 min ischemia and reperfusion. The tubuli are dilated and the lining epithelial cells are 
strongly flattened (arrows). Almost all of the tubuli show thyreoidisation (asterisks). The connective tissue 
contains a lot of pas-stained macrophages (arrowheads). e: extremely enlarged Bowman’s capsules in 
the cortex of a PACAP deficient mouse after 60 min ischemia and reperfusion are shown (triangle). 
F: Thyreoidisation (arrows) in the kidney of a wild-type mouse following 60 min ischemia and reperfusion
PACAP effects in renal ischemia 375
Acta Biologica Hungarica 65, 2014
react more sensitively to various stressors [35], including ischemic lesions. pacap 
deficient mice displayed larger infarcted area in a model of focal cerebral ischemia 
and the extent of the ischemic retinal lesion was also increased [43]. there are similar 
findings in peripheral tissues in ischemic lesions. A greater damage could be observed 
in PACAP deficient mice in case of intestinal ischemia while intact small intestine of 
deficient mice was similar to that of wild-type mice [9, 10]. We have also reported 
such findings in case of the kidneys of PACAP deficient mice [46]. Although histo-
logical evaluation showed no difference between the kidneys of intact wild-type and 
PACAP deficient mice, there was more severe tissue damage after ischemia/reperfu-
sion in PACAP deficient mice. Here we show a representative example of the 
increased vulnerability of PACAP deficient mice. Kidneys of PACAP deficient mice 
showed more severe morphological outcome after 45 or 60 min ischemia and 2 weeks 
reperfusion (Fig. 1). This is reflected in all tested histopathological parameters (dila-
tation of the Bowman’s capsule, tubular dilatation, thyreoidisation, lymphocyte- and 
macrophage infiltration, damage of the glycocalyx layer) [46]. We also determined 
cytokine expression and found an increased expression of several cytokines in 
PACAP deficient mice after ischemia/reperfusion, such as C5a, macrophage inflam-
matory protein-2 (mip-2), monocyte chemoattractant protein-1 (mcp-1), tissue 
metalloproteinase inhibitor-1 (TIMP-1), B-lymphocyte chemoattractant (BLC) [46]. 
Lower activity of the endogenous antioxidant SOD could be measured in control 
(sham-operated) PACAP deficient mice compared to the control wild-type mice. The 
activity of SOD decreased both in wild-type and PACAP deficient mice following 
ischemia/reperfusion. The extent of this decrease correlated to the baseline level was 
significant only in the PACAP deficient mice [46]. Based on the results can be con-
cluded that endogenous pacap has an effect on the antioxidant/scavenger system, 
and that PACAP deficient mice are more vulnerable to harmful stimuli.
Nephroprotective effect of endogenous PACAP in oxidative stress-induced kidney 
injury has also been revealed in vitro. Primary kidney cell cultures derived from 
PACAP deficient mice exposed to oxidative stress or in vitro hypoxia had decreased 
cell viability [14, 16] compared to the cultures of wild-type mice. This reduced cell 
viability could be counteracted by exogenously given PACAP38. 
In summary, the published results have revealed that both the exogenous and the 
endogenous pacap have a protective effect in renal ischemia/reperfusion in vivo as 
well as in vitro (summarized in Table 1). The antiapoptotic, anti-inflammatory and 
antioxidant effects of the peptide can all play an important role in this protective 
effect.
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